We employ a rigorously science-driven R&D strategy and have successfully built multiple proprietary technology platforms. These integrated platforms leverage AI and diverse antibody engineering capabilities, including LeadsBody (CD3 T-cell engager platform), X-body (4-1BB engager platform), and TOPiKinectics (ADC Platform).These platforms form the foundation for our continuous innovation across diverse targets, mechanisms of action (MOAs), and therapeutic modalities.

We have established integrated capabilities across early discovery, translational medicine, clinical development, CMC and business development. Building on our in-house innovations, we seek to forge strategic partnerships with different industry players and venture capitals to accelerate the clinical development and commercial launch of our drug candidates on a global scale, thereby maximizing the impact and reach of our transformative therapies.